James Albiero

James Albiero

Auto-generated profile, based on publicly available information

James Albiero

Univ Estadual Maringa, Maringa, Parana, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in American Journal of Infection Control
Verified
Journal Article
Closed access
ACAnaelís C. Campos
Anaelís C. Campos
JAJames Albiero
James Albiero
AEAlessandra B. Ecker
Alessandra B. Ecker
CKCristina M. Kuroda
Cristina M. Kuroda
LMLívia E.F. Meirelles
Lívia E.F. Meirelles
JTJorge J.V. Teixeira
Jorge J.V. Teixeira

1 June 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JAJames Albiero
James Albiero
JMJosmar Mazucheli
Josmar Mazucheli
JBJuliana Pimenta dos Reis Barros
Juliana Pimenta dos Reis Barros
MSMarcia Maria dos Anjos Szczerepa
Marcia Maria dos Anjos Szczerepa
SNSheila Alexandra Belini Nishiyama
Sheila Alexandra Belini Nishiyama
MTMaria Cristina Bronharo Tognim
Maria Cristina Bronharo Tognim
Fosfomycin combined with other antimicrobials has shown good efficacy against multidrug-resistant (MDR) bacteria in both in vitro and clinical studies; however, the activity of fosfomycin combined with other antimicrobials against metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa strains has not been tested. The objective of this study was to determine the synergism and optimal intravenous dosing regimens of fosfomycin with meropenem against MDR and MBL-producing P. aeruginosa strains.

1 July 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JAJames Albiero
James Albiero
SSSherwin Sy
Sherwin Sy
JMJosmar Mazucheli
Josmar Mazucheli
SCSilvana Martins Caparroz-Assef
Silvana Martins Caparroz-Assef
BCBruno Buranello Costa
Bruno Buranello Costa
MTMaria Cristina Bronharo Tognim
Maria Cristina Bronharo Tognim
KPC-producingKlebsiella pneumoniaecauses serious infections associated with high death rates worldwide. Combination therapy consisting of fosfomycin and a carbapenem is better than monotherapy to combat multidrug-resistant microorganisms, but no dosages for the combination have been defined. The MICs of meropenem and fosfomycin were evaluated against 18 clinical isolates of KPC-2-producingK. pneumoniae. The activities of combination antimicrobials were also determined by the checkerboard method. The MIC50and MIC90of each agent alone and in combination were challenged against short (1.5-h) or prolonged (3-h) infusion regimens of meropenem (1 g every 8 h [q8h], 1.5 g q6h, 2 g q8h) and fosfomycin (4 g q8h, 6 g q6h, 8 g q8h) by Monte Carlo simulation to evaluate the time above the MIC of the free drug concentration as a percentage of the dosing interval (fT>MIC). The monotherapy MIC50s and MIC90s were 32 and 256 mg/liter for meropenem and 64 and 512 mg/liter for fosfomycin, respectively. Antimicrobial combination increased bacterial susceptibility to 1/4 the MIC50s and to 1/8 to 1/16 the MIC90s of monotherapy. The antimicrobial combination demonstrated a synergistic effect for at least two-thirds of the isolates. In combination therapy, fosfomycin regimens of 6 g q6h and 8 g q8h as a 3-h infusion against the MIC50and MIC90had better chances of achieving ≥90% probability of target attainment (PTA) of 70%fT>MIC. Meropenem regimens of 1.5 g q6h and 2 g q8h in prolonged infusion can achieve close to 90% PTA of 40%fT>MIC for MIC50but not MIC90. The significant reduction in the MIC values and the achievement of appropriate PTA demonstrated that regimens containing fosfomycin with meropenem can be effective against KPC-2-producingK. pneumoniae.

1 August 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
NFNayara Helisandra Fedrigo
Nayara Helisandra Fedrigo
JMJosmar Mazucheli
Josmar Mazucheli
JAJames Albiero
James Albiero
DSDanielle Rosani Shinohara
Danielle Rosani Shinohara
FLFernanda Gomes Lodi
Fernanda Gomes Lodi
MTMaria Cristina Bronharo Tognim
Maria Cristina Bronharo Tognim
Fosfomycin is widely used for the treatment of uncomplicated urinary tract infection (UTI), and it has recently been recommended that fosfomycin be used to treat infections caused by multidrug-resistant (MDR) Gram-negative bacilli. Whether urine acidification can improve bacterial susceptibility to fosfomycin oral dosing regimens has not been analyzed. The MIC of fosfomycin for 245 Gram-negative bacterial isolates, consisting of 158 Escherichia coli isolates and 87 Klebsiella isolates which were collected from patients with urinary tract infections, were determined at pH 6.0 and 7.0 using the agar dilution method. Monte Carlo simulation of the urinary fosfomycin area under the concentration-time curve (AUC) after a single oral dose of 3,000 mg fosfomycin and the MIC distribution were used to determine the probability of target attainment (PTA). Fosfomycin was effective against E. coli (MIC 90 ≤ 16 μg/ml) but not against Klebsiella spp. (MIC 90 > 512 μg/ml). Acidification of the environment increased the susceptibility of 71% of the bacterial isolates and resulted in a statistically significant decrease in bacterial survival. The use of a regimen consisting of a single oral dose of fosfomycin against an E. coli isolate with an MIC of ≤64 mg/liter was able to achieve a PTA of ≥90% for a target pharmacodynamic index (AUC/MIC) of 23 in urine; PTA was not achieved when the MIC was higher than 64 mg/liter. The cumulative fractions of the bacterial responses (CFR) were 99% and 55% against E. coli and Klebsiella spp., respectively, based on simulated drug exposure in urine with an acidic pH of 6.0. A decrease of the pH from 7.0 to 6.0 improved the PTA and CFR of the target pharmacodynamic index in both E. coli and Klebsiella isolates.

31 October 2019 in Microbial Drug Resistance
Verified
Journal Article
Closed access
TMThatiany Cevallos Menegucci
Thatiany Cevallos Menegucci
NFNayara Helisandra Fedrigo
Nayara Helisandra Fedrigo
FLFernanda Gomes Lodi
Fernanda Gomes Lodi
JAJames Albiero
James Albiero
SNSheila Alexandra Belini Nishiyama
Sheila Alexandra Belini Nishiyama
MTMaria Cristina Bronharo Tognim
Maria Cristina Bronharo Tognim
Aim: The aims of the study are to evaluate the activity of sulbactam, meropenem, and polymyxin B alone and in combination against six isolates of extremely drug resistant Acinetobacter baumannii and to determine dosing regimens that achieve a sufficient joint probability of target attainment (PTA) based on combination antimicrobial pharmacodynamics. Materials and Methods: The combinations were evaluated by the checkerboard method and were considered synergistic when the fractional inhibitory concentration index (FICI) ≤0.5. Pharmacodynamic analyses were carried out by evaluating dosing regimens that achieve ≥90% joint PTA at the percentage of time over a 24-h period wherein the free drug concentration is above the minimum inhibitory concentration (% f T> MIC) of 40% and 60% for meropenem and sulbactam, respectively, and 20 for the ratio of the area under the free drug concentration-time curve over MIC ( f AUC/MIC) for polymyxin B. Results: For both polymyxin B-resistant and susceptible isolates, the addition of sulbactam in combination with meropenem and subinhibitory concentration of polymyxin B showed important synergistic activity (five isolates; FICI ≤0.281); the recommended dosing regimens were 2/4 g meropenem/sulbactam q8 hours and 0.5 mg/kg polymyxin B q12 hours. Conclusion: This in vitro study showed that sulbactam can significantly improve the action of meropenem and polymyxin B in OXA-producing A. baumannii isolates, especially when there are no new treatment options available for infections caused by these microorganisms.

1 May 2016 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
TMThatiany Cevallos Menegucci
Thatiany Cevallos Menegucci
JAJames Albiero
James Albiero
LMLetícia Busato Migliorini
Letícia Busato Migliorini
JAJanio Leal Borges Alves
Janio Leal Borges Alves
GVGiselle Fukita Viana
Giselle Fukita Viana
MTMaria Cristina Bronharo Tognim
Maria Cristina Bronharo Tognim